APOTEX-MYCOPHENOLATE mycophenolate mofetil 250 mg capsule blister pack

País: Australia

Idioma: inglés

Fuente: Department of Health (Therapeutic Goods Administration)

Ingredientes activos:

mycophenolate mofetil, Quantity: 250 mg

Disponible desde:

Arrotex Pharmaceuticals Pty Ltd

Designación común internacional (DCI):

Mycophenolate mofetil

formulario farmacéutico:

Capsule

Composición:

Excipient Ingredients: croscarmellose sodium; indigo carmine; Gelatin; titanium dioxide; purified water; iron oxide red; magnesium stearate; sodium lauryl sulfate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; Shellac; strong ammonia solution; iron oxide black; potassium hydroxide

Vía de administración:

Oral

Unidades en paquete:

100 capsules, 300 capsules

tipo de receta:

(S4) Prescription Only Medicine

indicaciones terapéuticas:

Mycophenolate mofetil is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants.,Mycophenolate mofetil is indicated for the prophylaxis of organ rejection in paediatric patients (2 to 18 years) receiving allogeneic renal transplants.

Resumen del producto:

Visual Identification: Opaque blue cap and opaque pink body in Size 1 capsule containing white to off white powder. "M250" and "APO" are imprinted on capsules in black ink.; Container Type: Blister Pack; Container Material: PVC/PVDC/Al; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius

Estado de Autorización:

Licence status A

Fecha de autorización:

2011-11-08